IP Library Granted Patent US 8,062,852
Granted Patent B2
US 8,062,852 · App. 12/243,913 · Granted Nov 22, 2011

Detection and treatment of autoimmune disorders

Assignee: The Children's Hospital and Regional Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,062,852
App. No.
12/243,913
Granted
Nov 22, 2011
Kind
B2
Abstract

Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand.

Claims (17)

1. A method of diagnosing systemic lupus erythematosus (SLE) in a human individual comprising:

determining the PD-L1 level in a blood sample obtained from said individual;

comparing the PD-L1 level to a reference PD-L1 level, wherein said reference PD-L1 level is derived from the PD-L1 level in one or more individuals that do not have SLE; and

diagnosing said individual as having SLE when the PD-L1 level is less than said reference PD-L1 level or identifying said individual as not having SLE when the PD-L1 level is not less than said reference PD-L1 level.

2. The method of claim 1 , wherein the blood sample comprises peripheral blood lymphocytes.

3. The method of claim 1 , wherein said PD-L1 level is determined using an antibody that is specific for PD-L1.

4. The method of claim 3 , further comprising providing the use of an antibody specific for a to cell surface marker on a monocyte or dendritic cell.

5. The method of claim 3 , wherein the antibody is fluorescently-labeled.

6. The method of claim 1 , wherein the determining step employs flow cytometry.

7. The method of claim 1 , wherein the PD-L1 level is the amount of PD-L1 in the blood sample.

8. The method of claim 1 , wherein the PD-L1 level is the number of cells in the blood sample that express PD-L1.

9. The method of claim 8 , wherein the cells comprise peripheral blood mononuclear cells (PBMCs).

10. The method of claim 8 , wherein the cells comprise antigen-presenting cells (APCs).

11. The method of claim 10 , wherein the APCs comprise monocytes.

12. The method of claim 11 , wherein the monocytes comprise CD14+/CD11c+ monocytes.

13. The method of claim 10 , wherein the APCs comprise myeloid dendritic cells (mDC).

14. The method of claim 13 , wherein the myeloid dendritic cells comprise CD14 −/LO /CD11c+ myeloid dendritic cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2011
From: MOZAFFARIAN, NEELUFAR; STEVENS, ANNE M.
To: THE CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER
Reel/Frame 025862/0825 →
CHANGE OF NAME Recorded Dec 2, 2008
From: CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER
To: SEATTLE CHILDREN'S HOSPITAL
Reel/Frame 021916/0346 →
Continuity (2)
Provisional Application 60997334 · Oct 1, 2007
Related Publication 20090110667A1 · Apr 30, 2009